IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2019
Review paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer
/in Publications /by Pantarhei BioscienceReview paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer
Estrogens are known to stimulate the growth of breast cancer, whereas on the other hand estrogens are an effective treatment for this disease. The fact that estrogens can effectively be used for the treatment of breast cancer is something that almost has been forgotten about, whereas the fear for estrogens remains. This paper reviews the use of estrogens for the treatment of breast cancer and identifies possible applications for the future.
Coelingh Bennink et al Maturitas 2017 (HDE paper)
Results Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men published in The Journal of Clinical Endocrinology & Metabolism
/in Publications /by Pantarhei BioscienceLuteinizing hormone–releasing hormone agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The published study with the fetal estrogen estetrol (E4) in healthy males shows promise as a safe and effective drug for use in prostate cancer.
A Dose-Escalating Study With the Fetal Estrogen JCEM 2018
16th World congress on Menopause, June 6-9, 2018, Vancouver, Canada
/in News /by Pantarhei BioscienceOn Friday June 8, 2018, the CSO of Pantarhei Carole Verhoeven lectured on the treatment of breast cancer with the fetal estrogen estetrol in a scientific symposium entitled ‘Estrogens and breast cancer’. The other lecture (A lesson in contracts. What can we learn from the discrepant breast cancer findings in the WHI?) was presented by Bob Langer. The symposium was chaired by Wulf Utian.
For more information, please read the abstract: Abstract IMS Treatment of breast cancer with the fetal estrogen estetrol.